𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma : A Cancer and Leukemia Group B study

✍ Scribed by Ellis G. Levine; Susan Halabi; John D. Roberts; Ellen B. Kaplan; Randall Rago; James N. Atkins; Nicholas J. Vogelzang

Book ID
102105160
Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
85 KB
Volume
94
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The dynamics of prostate specific antige
The dynamics of prostate specific antigen in hormone refractory prostate carcinoma : An analysis of Cancer and Leukemia Group B Study 9181 of megestrol acetate
✍ Robin T. Vollmer; Nancy A. Dawson; Nicholas J. Vogelzang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## BACKGROUND. Although many physicians measure serum prostate specific antigen (PSA) during the follow-up of patients with hormone refractory prostate carcinoma (HRPC), little has been done to formalize the determination of how these serial values of PSA impact on prognosis. To understand HRPC fu

A Phase II study of estramustine, doceta
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyte–colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813
✍ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB 👁 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte–colony‐stimulating factor (G‐CSF) support in patients with hormone‐refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,